Eckert & Ziegler Strahlen- und Medizintechnik AG (DE:EUZ)
XETRA:EUZ
EUZ Stock Chart & Stats
€14.57
-€1.00(-2.03%)
At close: 4:00 PM EST
€14.57
-€1.00(-2.03%)
Day’s Range― - ―
52-Week Range€13.30 - €23.25
Previous CloseN/A
Volume2.14K
Average Volume (3M)108.96K
Market Cap
€911.70M
Enterprise Value€827.82M
Total Cash (Recent Filing)€128.76M
Total Debt (Recent Filing)€44.80M
Price to Earnings (P/E)19.6
Beta1.24
Next Earnings
May 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.11%
Share Statistics
EPS (TTM)0.30
Shares Outstanding63,515,797
10 Day Avg. Volume81,969
30 Day Avg. Volume108,959
Financial Highlights & Ratios
PEG Ratio0.42
Price to Book (P/B)3.79
Price to Sales (P/S)3.06
P/FCF Ratio27.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€22.15Price Target Upside52.02% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.83
Revenue Forecast (FY)€338.93M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetLow leverage and rising equity provide durable financial flexibility: the company can fund regulatory compliance, capacity investment or small M&A without large refinancing needs. A conservative balance sheet reduces solvency risk and interest expense sensitivity across cycles.
Multi-year Revenue Expansion & Solid EBITSustained top-line growth combined with strong operating earnings demonstrates a scalable radiopharma business model. Reliable EBIT at scale supports reinvestment in production capacity, regulatory processes and product development, underpinning long-term competitiveness.
Generally Positive Operating Cash FlowConsistently healthy operating cash flow funds operations, maintenance capex and working capital without heavy external financing. This recurring cash generation strengthens self-funding ability for capital needs and cushions the business through regulatory or demand cycles.
Bears Say
Volatile Free Cash FlowWide swings in free cash flow reduce predictability of internal funding and complicate capital allocation. Volatility may force ad hoc financing or constrain dividends and reinvestment during weaker years, increasing execution risk for long-term projects.
Recent Growth Deceleration & Margin VariabilityUneven revenue growth and softer margins indicate the company faces pricing, mix or cost pressures that could persist. This variability makes earnings power less predictable and may limit sustained margin expansion unless structural drivers are addressed.
Modest Recent Revenue Growth RateA roughly 5.4% revenue growth rate is modest for a specialized medical-technology firm and may lag peers or market potential. Slower top-line expansion limits scale economies, reduces optionality for new investments, and constrains long-term profit growth.
Eckert & Ziegler Strahlen und Medizintechnik News
EUZ FAQ
What was Eckert & Ziegler Strahlen- und Medizintechnik AG’s price range in the past 12 months?
Eckert & Ziegler Strahlen- und Medizintechnik AG lowest stock price was €13.30 and its highest was €23.25 in the past 12 months.
What is Eckert & Ziegler Strahlen- und Medizintechnik AG’s market cap?
Eckert & Ziegler Strahlen- und Medizintechnik AG’s market cap is €911.70M.
When is Eckert & Ziegler Strahlen- und Medizintechnik AG’s upcoming earnings report date?
Eckert & Ziegler Strahlen- und Medizintechnik AG’s upcoming earnings report date is May 12, 2026 which is in 37 days.
How were Eckert & Ziegler Strahlen- und Medizintechnik AG’s earnings last quarter?
Eckert & Ziegler Strahlen- und Medizintechnik AG released its earnings results on Mar 26, 2026. The company reported €0.302 earnings per share for the quarter, beating the consensus estimate of N/A by €0.302.
Is Eckert & Ziegler Strahlen- und Medizintechnik AG overvalued?
According to Wall Street analysts Eckert & Ziegler Strahlen- und Medizintechnik AG’s price is currently Undervalued.
Does Eckert & Ziegler Strahlen- und Medizintechnik AG pay dividends?
Eckert & Ziegler Strahlen- und Medizintechnik AG pays a Annually dividend of €0.167 which represents an annual dividend yield of 1.11%. See more information on Eckert & Ziegler Strahlen- und Medizintechnik AG dividends here
What is Eckert & Ziegler Strahlen- und Medizintechnik AG’s EPS estimate?
Eckert & Ziegler Strahlen- und Medizintechnik AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Eckert & Ziegler Strahlen- und Medizintechnik AG have?
Eckert & Ziegler Strahlen- und Medizintechnik AG has 63,515,797 shares outstanding.
What happened to Eckert & Ziegler Strahlen- und Medizintechnik AG’s price movement after its last earnings report?
Eckert & Ziegler Strahlen- und Medizintechnik AG reported an EPS of €0.302 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 6.351%.
Which hedge fund is a major shareholder of Eckert & Ziegler Strahlen- und Medizintechnik AG?
Currently, no hedge funds are holding shares in DE:EUZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Eckert & Ziegler Strahlen und Medizintechnik Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€22.15 (52.02% Upside)
€22.15 (52.02% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
20.79%
12-Months-Change
Fundamentals
Return on Equity
20.78%
Trailing 12-Months
Asset Growth
3.28%
Trailing 12-Months
Company Description
Eckert & Ziegler Strahlen- und Medizintechnik AG
Eckert & Ziegler Strahlen- und Medizintechnik AG, through its subsidiaries, manufactures and sells isotope technology components for medical, scientific, and industrial applications worldwide. It operates in two segments, Medical and Isotope Products. The Medical segment offers small radioactive implants for the treatment of prostate cancer seeds; and eye application based on ruthenium-106 or iodine-125 for treating uveal melanoma. This segment also provides radiopharmaceuticals, laboratory equipment, hot cells, and services for radiopharmaceuticals, as well as eye applicators and prostate implants. The Isotope Products segment manufactures and sells radiation sources for imaging, measurement technology, material analysis, quality assurance, and environmental monitoring. This segment also offers calibration sources for medical imaging systems, and homeland security and radiometric level measurement products. The company was founded in 1992 and is headquartered in Berlin, Germany.
EUZ Stock 12 Month Forecast
Average Price Target
€22.15
▲(52.02% Upside)
Technical Analysis
Gerresheimer
―
MeVis Medical Solutions
―
STRATEC Biomedical
―
Siemens Healthineers AG
―
MagForce AG
―
Options Prices
Currently, No data available
---